Ignite Creation Date:
2025-12-24 @ 5:43 PM
Ignite Modification Date:
2026-04-13 @ 9:29 PM
Study NCT ID:
NCT00724568
Status:
COMPLETED
Last Update Posted:
2017-06-02
First Post:
2008-04-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
UMCC 2007.098
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None